Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3692)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION OF "PEG SIHEMATIDE INJECTIONS" ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

The board of directors (the "**Board**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") is pleased to announce that New Drug Application (NDA) of "PEG Sihematide injections" was accepted by the National Medical Products Administration ("**NMPA**"). "PEG Sihematide injections" is a class 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), a subsidiary of the Company. This drug is intended for the treatment of dialysis patients who are receiving erythropoietin treatment due to anemia caused by chronic kidney disease (CKD).

About "PEG Sihematide injections" (HS-20039)

"PEG Sihematide injections", a class 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), is a long-acting new peptide erythropoietin (EPO) agonist. A pivotal phase III study conducted in EPO treated dialysis anemia patients demonstrated that "PEG Sihematide injections" reached the primary efficacy endpoint and showed superiority. It also showed good safety and tolerability in healthy people and renal anemia patients. Compared with Lixuebao (Recombinant Human Erythropoietin Injection (CHO Cell)), "PEG Sihematide injections" did not increase the risk of cardiovascular events and had potential favorable safety profile and patients compliance.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, October 4, 2021

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.